Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide.
Solid track record with adequate balance sheet.
Share Price & News
How has Siemens Healthineers's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SHL has not had significant price volatility in the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: SHL underperformed the German Medical Equipment industry which returned 20.4% over the past year.
Return vs Market: SHL exceeded the German Market which returned 3% over the past year.
Price Volatility Vs. Market
How volatile is Siemens Healthineers's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHere's Why I Think Siemens Healthineers (ETR:SHL) Might Deserve Your Attention Today
1 month ago | Simply Wall StEstimating The Intrinsic Value Of Siemens Healthineers AG (ETR:SHL)
2 months ago | Simply Wall StDoes Siemens Healthineers AG's (ETR:SHL) P/E Ratio Signal A Buying Opportunity?
Is Siemens Healthineers undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: SHL (€41.95) is trading below our estimate of fair value (€46.14)
Significantly Below Fair Value: SHL is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: SHL is good value based on its PE Ratio (26.9x) compared to the Medical Equipment industry average (53x).
PE vs Market: SHL is poor value based on its PE Ratio (26.9x) compared to the German market (21.1x).
Price to Earnings Growth Ratio
PEG Ratio: SHL is poor value based on its PEG Ratio (2x)
Price to Book Ratio
PB vs Industry: SHL is good value based on its PB Ratio (4.4x) compared to the DE Medical Equipment industry average (4.5x).
How is Siemens Healthineers forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SHL's forecast earnings growth (13.3% per year) is above the savings rate (0.2%).
Earnings vs Market: SHL's earnings (13.3% per year) are forecast to grow slower than the German market (22.4% per year).
High Growth Earnings: SHL's earnings are forecast to grow, but not significantly.
Revenue vs Market: SHL's revenue (5.7% per year) is forecast to grow slower than the German market (5.9% per year).
High Growth Revenue: SHL's revenue (5.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SHL's Return on Equity is forecast to be low in 3 years time (16.8%).
How has Siemens Healthineers performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SHL has high quality earnings.
Growing Profit Margin: SHL's current net profit margins (10.4%) are higher than last year (9.9%).
Past Earnings Growth Analysis
Earnings Trend: SHL's earnings have grown by 4.2% per year over the past 5 years.
Accelerating Growth: SHL's earnings growth over the past year (13.8%) exceeds its 5-year average (4.2% per year).
Earnings vs Industry: SHL earnings growth over the past year (13.8%) exceeded the Medical Equipment industry 8.2%.
Return on Equity
High ROE: SHL's Return on Equity (16.4%) is considered low.
How is Siemens Healthineers's financial position?
Financial Position Analysis
Short Term Liabilities: SHL's short term assets (€7.6B) exceed its short term liabilities (€6.0B).
Long Term Liabilities: SHL's short term assets (€7.6B) exceed its long term liabilities (€7.4B).
Debt to Equity History and Analysis
Debt Level: SHL's debt to equity ratio (63.2%) is considered high.
Reducing Debt: Insufficient data to determine if SHL's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: SHL's debt is well covered by operating cash flow (28.4%).
Interest Coverage: SHL's interest payments on its debt are well covered by EBIT (89.2x coverage).
What is Siemens Healthineers's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: SHL's dividend (1.91%) is higher than the bottom 25% of dividend payers in the German market (1.26%).
High Dividend: SHL's dividend (1.91%) is low compared to the top 25% of dividend payers in the German market (3.8%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, SHL has been paying a dividend for less than 10 years.
Growing Dividend: SHL's dividend payments have increased, but the company has only paid a dividend for 2 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (51.4%), SHL's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: SHL's dividends in 3 years are forecast to be covered by earnings (51.6% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bernd Montag (51yo)
Dr. Bernhard Montag, also known as Bernd, serves as President and at Chairman of Management Board Siemens at Healthineers AG and has been its Chief Executive Officer and Member of Management Board since 20 ...
CEO Compensation Analysis
Compensation vs Market: Bernd's total compensation ($USD4.52M) is about average for companies of similar size in the German market ($USD5.21M).
Compensation vs Earnings: Bernd's compensation has increased by more than 20% in the past year.
|CFO & Member of Management Board||2.58yrs||€2.77m||no data|
|Member of Management Board||0.75yr||no data||no data|
|Head of Investor Relations||no data||no data||no data|
|President of Advanced Therapies||no data||no data||no data|
|Head of Finance Diagnostics||no data||no data||no data|
|Executive Vice President of Finance||no data||no data||no data|
|President of Laboratory Diagnostics||no data||no data||no data|
Experienced Management: SHL's management team is considered experienced (2.6 years average tenure).
|Deputy Chairman of Supervisory Board||2.5yrs||€193.00k||no data|
|Independent Member of Supervisory Board||2.33yrs||€147.63k||no data|
|Chairman of Supervisory Board||0.58yr||no data||no data|
|Independent Member of Supervisory Board||2.33yrs||€171.00k||no data|
|Member of Supervisory Board||0.42yr||no data||no data|
|Independent Member of Supervisory Board||2.33yrs||€123.50k||no data|
|Member of Supervisory Board||2.33yrs||€117.93k||no data|
|Member of Supervisory Board||2.33yrs||€201.50k||no data|
|Independent Member of Supervisory Board||2.33yrs||€162.50k||no data|
Experienced Board: SHL's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Siemens Healthineers AG's company bio, employee growth, exchange listings and data sources
- Name: Siemens Healthineers AG
- Ticker: SHL
- Exchange: XTRA
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €42.117b
- Shares outstanding: 997.80m
- Website: https://www.siemens-healthineers.com
Number of Employees
- Siemens Healthineers AG
- Henkestrasse 127
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SHL||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Mar 2018|
|SHL||WBAG (Wiener Boerse AG)||Yes||Ordinary Shares||AT||EUR||Mar 2018|
|SHL||SWX (SIX Swiss Exchange)||Yes||Ordinary Shares||CH||CHF||Mar 2018|
|SHL||XTRA (XETRA Trading Platform)||Yes||Ordinary Shares||DE||EUR||Mar 2018|
|SHLD||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Mar 2018|
|SEMH.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Mar 2018|
|0PMJ||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Mar 2018|
|SHL||ETLX (Eurotlx)||Yes||Ordinary Shares||IT||EUR||Mar 2018|
|SMMN.Y||OTCPK (Pink Sheets LLC)||UNSPONSORED ADR||US||USD||May 2018|
|SHL1||DB (Deutsche Boerse AG)||UNSPONSORED ADR||DE||EUR||May 2018|
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and distributes imaging, diagnostic, and advanced therapies products and services to healthcare providers worldwide. The company’s Imaging segment offers magnetic resonance, computed tomography, X-ray, molecular imaging, and ultrasound systems. Its Diagnostics segment provides in-vitro diagnostic products and services to healthcare providers in laboratory, molecular, and point-of-care diagnostics; and workflow solutions and informatics products. The company’s Advanced Therapies segment offers integrated products, solutions, and services for therapy departments of healthcare providers. This segment’s principal products include angiography systems and mobile C-arms. It also provides customer value chain services, including design, maintenance, operational management, training, and education services. Siemens Healthineers AG has a collaboration agreement with MicroPort Scientific Corp. to develop medical imaging equipment used in diagnostics and operating procedures. The company is headquartered in Erlangen, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/07 20:50|
|End of Day Share Price||2020/07/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.